GlassScriptPhysician profile
Donna W Turner
NPI 1851346365
$1,496.21
in general payments reported to CMS, 2019-2025
33 companies · $34.22 in 2025
The $34.22 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $409 · 2023: $538 · 2024: $88.67 · 2025: $34.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $278.12 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $149.58 | 2021-2023 | Imbruvica |
| Eisai INC. | $119.90 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $99.75 | 2023 | Gemtesa |
| Janssen Biotech, INC. | $97.48 | 2021-2023 | Erleada |
| Celgene Corporation | $71.53 | 2021-2023 | Reblozyl |
| Mayne Pharma Commercial LLC | $71.51 | 2023 | |
| Glaxosmithkline, LLC. | $54.19 | 2021-2024 | Ojjaara, Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $52.19 | 2022-2023 | |
| Astellas Pharma US INC | $43.00 | 2022-2025 | Padcev |
| Abbvie INC. | $35.93 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $32.70 | 2021-2023 | Calquence |
| Deciphera Pharmaceuticals INC. | $32.37 | 2021-2022 | |
| Exelixis INC. | $30.34 | 2021 | |
| Incyte Corporation | $28.64 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.61 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $27.32 | 2023 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $21.35 | 2022 | |
| Blueprint Medicines Corporation | $20.72 | 2023 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $17.28 | 2023 | Fotivda |
| Merck Sharp & Dohme LLC | $16.49 | 2022 | |
| Coherus Oncology, INC. | $16.30 | 2022 | |
| Seagen INC. | $15.63 | 2021 | |
| Puma Biotechnology, INC. | $15.25 | 2023 | Nerlynx |
| Evofem Biosciences, INC. | $14.94 | 2022 | |
| Horizon Therapeutics Plc | $14.48 | 2022 | |
| Daiichi Sankyo INC. | $13.81 | 2021 | |
| Karyopharm Therapeutics INC. | $13.46 | 2021 | |
| Array Biopharma INC | $13.42 | 2021 | |
| Scynexis, INC. | $13.09 | 2022 | |
| Beigene USA, INC. | $12.66 | 2021 | |
| Kite Pharma, INC. | $12.19 | 2021 | |
| Lilly USA, LLC | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.